CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2021
OPERATING ACTIVITIES:
Net loss	$ (30,859)		$ (31,819)	$ (25,325)
Adjustments to reconcile net loss to net cash provided by operating activities:
Provision for bad debt	3,142	[1]	(1,097)	1,135
Depreciation and amortization	45,780		47,479	44,810
Amortization of right-of-use asset	10,194		9,289	8,151
Stock-based compensation expense	47,267		43,290	10,321
Fair value changes in financial instruments	(4,129)		(3,396)	2,195
Fair value changes in business acquisition contingencies	84		(3,227)	24,372
Deferred income taxes	(980)		2,250	1,709
Debt extinguishment costs				4,052
Other	(84)		349	(195)
Changes in operating assets and liabilities—net of acquisitions:
Accounts receivable and contract assets	(2,923)		4,394	(36,164)
Prepaid expenses and other current assets	(918)		(1,763)	(1,148)
Accounts payable and other accrued liabilities	(8,912)		(9,878)	23,996
Accrued payroll and benefits	9,464		(6,830)	3,244
Payment of contingent consideration	(611)		(19,457)	(15,628)
Change in operating leases	(10,493)		(8,935)	(7,944)
Net cash provided by operating activities	56,022		20,649	37,581
INVESTING ACTIVITIES:
Proceeds from corporate owned and property insurance	573		329	413
Purchases of property and equipment	(29,578)		(9,583)	(6,885)
Proceeds from the sale of property and equipment	971		174	597
Proprietary software development and other software costs	(3,352)		(593)	(699)
Payment of purchase price true ups	(1,425)		(389)	(9,336)
Minority investments	(2,626)
Cash paid for acquisitions—net of cash acquired	(66,187)		(28,625)	(55,731)
Net cash used in investing activities	(101,624)		(38,687)	(71,641)
FINANCING ACTIVITIES:
Proceeds from line of credit				109,000
Repayment of the line of credit				(109,000)
Proceeds from term loans				175,000
Repayment of term loans	(12,211)		(8,750)	(173,905)
Proceeds from the aircraft loan	10,935
Repayment of aircraft loan	(591)
Payment of contingent consideration and other purchase price true ups	(1,949)		(11,107)	(9,865)
Repayment of finance leases	(4,584)		(3,967)	(2,711)
Proceeds from issuance of common stock in public offerings, net of issuance costs				169,783
Payments of deferred offering costs			(183)	(446)
Debt issuance cost				(2,590)
Proceeds from issuance of common stock for exercised stock options	4,690		1,643	7,237
Dividend payment to the series A-2 shareholders	(16,400)		(16,400)	(16,400)
Net cash (used in) provided by financing activities	(20,110)		(38,764)	146,103
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(65,712)		(56,802)	112,043
Foreign exchange impact on cash balance	(876)		(111)	(183)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Beginning of year	89,828		146,741	34,881
End of year	23,240		89,828	146,741
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:
Cash paid for interest, net	8,059		6,514	5,012
Cash paid for income tax, net	997		789	412
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued purchases of property and equipment	1,098		2,261	790
Property and equipment purchased under finance leases	8,298		5,061	1,766
Accrued lease surrender liability (Note 7)	5,947
Common stock issued to acquire new businesses	2,598			8,320
Acquisitions unpaid contingent consideration	6,040		$ 8,255	35,800
Acquisitions contingent consideration paid in shares	1,000			26,084
Offering costs included in accounts payable and other accrued liabilities				$ 183
Promissory note receivable issued in connectionwith the sale of assets of the Discontinued Specialty Lab (Note 19)	$ 4,348

[1] Amount includes $2.2 million of current expected losses on the Discontinued Specialty Lab promissory note receivable as described in Note 19.